{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Rombach I"],"funding":["Research Trainees Coordinating Centre","EPA","National Institute for Health Research (NIHR)"],"pagination":["1759720X211057668"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8756359"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13"],"pubmed_abstract":["<h4>Introduction</h4>In psoriatic arthritis (PsA), treatment recommendations support first-line use of disease-modifying antirheumatic drugs (DMARDs). There are few treatment strategy trials, and no previous studies have investigated tailored treatment choice by disease severity. Studies in oligoarthritis (<5 inflamed joints) are limited but have suggested that some can be managed without DMARDs, preventing unnecessary side effects. This study aimed to assess the feasibility and acceptability of a study comparing standard DMARD treatment against symptomatic therapy in patients with mild psoriatic oligoarthritis.<h4>Methods</h4>This trial was embedded within the MONITOR-PsA cohort, which uses a Trials Within Cohorts (TWiCs) design. Patients with newly diagnosed psoriatic oligoarthritis, wit"],"journal":["Therapeutic advances in musculoskeletal disease"],"pubmed_title":["Clinical effectiveness of symptomatic therapy compared with standard step-up care for the treatment of low-impact psoriatic oligoarthritis: the two-arm parallel group randomised POISE feasibility study."],"pmcid":["PMC8756359"],"funding_grant_id":["CL-2011-02-001","CS-2016-16-016","EP-C-16-016"],"pubmed_authors":["Coates LC","Tillett W","Francis A","Rombach I","Jadon D","Watson M","Sinomati Y","Tucker L","Dutton SJ"],"additional_accession":[]},"is_claimable":false,"name":"Clinical effectiveness of symptomatic therapy compared with standard step-up care for the treatment of low-impact psoriatic oligoarthritis: the two-arm parallel group randomised POISE feasibility study.","description":"<h4>Introduction</h4>In psoriatic arthritis (PsA), treatment recommendations support first-line use of disease-modifying antirheumatic drugs (DMARDs). There are few treatment strategy trials, and no previous studies have investigated tailored treatment choice by disease severity. Studies in oligoarthritis (<5 inflamed joints) are limited but have suggested that some can be managed without DMARDs, preventing unnecessary side effects. This study aimed to assess the feasibility and acceptability of a study comparing standard DMARD treatment against symptomatic therapy in patients with mild psoriatic oligoarthritis.<h4>Methods</h4>This trial was embedded within the MONITOR-PsA cohort, which uses a Trials Within Cohorts (TWiCs) design. Patients with newly diagnosed psoriatic oligoarthritis, wit","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021","modification":"2025-05-29T19:17:06.222Z","creation":"2022-02-11T16:19:36.305Z"},"accession":"S-EPMC8756359","cross_references":{"pubmed":["35035537"],"doi":["10.1177/1759720X211057668"]}}